slides · global inventory
Complication
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 25,056
Current window 17,221-17,250
Pages 836
Rows per page 30
Beat
17,221-17,250 of 25,056
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
16
Includes FDA approval precedents in the footer to establish credibility.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
17
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
18
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
19
The slide uses a side-by-side comparison structure to explain two distinct but complementary technology platforms.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
20
The table uses a standard pharmaceutical pipeline format, categorizing by clinical vs preclinical status and highlighting specific regulatory and clinical trial milestones.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
21
Combines market sizing data with a 'Why Now' narrative supported by industry news clippings and a comparative efficacy table.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Golden Circle1 hit
22
The slide uses a wave-like visual to represent market segments and their associated valuations.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Golden Circle1 hit
23
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
24
The slide uses a red dashed box to highlight the primary efficacy metrics (response rates).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
25
The chart uses a grouped bar structure to compare efficacy across patient segments (No BCMA, Yes BCMA, Overall).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
26
The slide uses a comparison table framework to highlight competitive advantage in clinical metrics.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
27
The slide uses a two-column layout to compare clinical data for two different indications, supported by competitor market data.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
05
The slide uses a process-oriented layout to show four strategic pillars leading to a unified outcome.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Early Struggles1 hit
06
The slide uses a timeline to show the divestment of non-luxury assets and acquisition of luxury brands, alongside donut charts to illustrate the shift in revenue composition.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Early Struggles1 hit
07
The slide uses a mix of brand logos and a bar chart to illustrate portfolio composition and financial scale.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Early Struggles1 hit
08
Uses a before-after framework to illustrate strategic evolution.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
04
Uses a visual icon array to represent the '1 in 4' statistic.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
03
The slide uses a generic pie chart graphic as a visual metaphor for market segmentation.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProblemLoop · Logic Chain1 hit
04
Uses authority citation (Forbes) to establish the scale of the problem.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProblemLoop · Logic Chain1 hit
09
The slide uses a comparative structure to justify the strategic shift in trial design post-acquisition.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · ComplicationLoop · Cost Of Inaction1 hit
10
Graphs depict prespecified statistical sensitivity analysis for moderate-to-severe patients (n=100; baseline HAMD-17 >= 22).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · ComplicationLoop · Cost Of Inaction1 hit
02
P3 Health Partners | Investor Conference Presentation Deck | 19 slidesP3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Beat · Interest1 hit
03
P3 Health Partners | Investor Conference Presentation Deck | 19 slidesP3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Beat · Interest1 hit
04
P3 Health Partners | Investor Conference Presentation Deck | 19 slidesP3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Beat · Interest1 hit
05
The slide uses a 'Right X' repetition structure to frame the investment thesis.P3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Beat · Interest1 hit
03
Pathward Financial | Investor Presentation Deck | 23 slidesPathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations Beat · ProblemLoop · Golden Circle1 hit
04
The timeline shows a transition from a traditional savings and loan bank to a diversified financial services company focused on BaaS and national banking.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations Beat · ProblemLoop · Golden Circle1 hit
09
The slide uses a comparison framework to justify the use of alpha-emitting isotopes in targeted radiotherapy.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · Problem1 hit
10
The slide uses a chronological progression of therapeutic classes (Targeted, Immuno-oncology, ADCs, Cell Therapy) leading to RPT.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · ProblemLoop · Why Now1 hit